Regarding the PC group, eight patients (53.3%) received anti-IL-17 biologics, six patients (40%) were treated with anti-IL-23 agents, and one patient (6.7%) received treatment with anti-IL-12/23. This evidence concerns the gene IL17A and pachyonychia congenita.